Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Oryzon Genomics S.A.
Headquarters:
Barcelona, Spain
Website:
https://www.oryzon.com/en
Year Founded:
2000
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Carlos Manuel Buesa Arjol, PhD
Number Of Employees:
46
Enterprise Value:
$102,705,550
PE Ratio:
-45.85
Exchange/Ticker 1:
Madrid:ORY
Exchange/Ticker 2:
N/A
Latest Market Cap:
$230,204,229
BioCentury
|
Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
Read More
BioCentury
|
Sep 12, 2023
Emerging Company Profile
Actio seeks rare toeholds into common diseases with $55M A round
Led by geneticist David Goldstein, the San Diego company thinks its ‘one-to-many’ strategy builds the economic case for going after very rare diseases
Read More
BioCentury
|
Jan 11, 2023
Management Tracks
Kevin Tan becomes CFO at Solid
Plus: Shook promoted to CMO at Nkarta, and updates from HilleVax, Neurotech, Akero, LifeSci, Dunad and more
Read More
BioCentury
|
Nov 21, 2022
Deals
High-premium Imago takeout gives Merck hematology asset nearing Phase III
Public since 2021, biotech led by former FerroKin team generates final exit at ten-figure price
Read More
BioCentury
|
Mar 28, 2022
Management Tracks
Asif Ali to join Protagonist as CFO
Plus new CMO at Avenge Bio, new CEO at
Read More
BioCentury
|
Jan 15, 2022
Management Tracks
Founder El-Hibri to retire from Emergent
Plus CEO Sandanayaka shifts to CSO at Nirogy, and updates from Angelini, Apie,
Read More
BioCentury
|
Dec 6, 2018
Translation in Brief
Opening chromatin: long-term detriment?
Enhancing chromatin accessibility in cancer could be a liability, not a benefit
Read More
BioCentury
|
Dec 8, 2017
Targets & Mechanisms
Epiphenomena at ASH
Epigenetics and cell therapies are preclinical hotspots at ASH 2017
Read More
BioCentury
|
Jul 21, 2017
Company News
Roche ends cancer deal with Oryzon
Read More
BioCentury
|
Jul 20, 2017
Company News
Roche ends cancer deal with Oryzon
Read More
Items per page:
10
1 - 10 of 28
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help